ESLA is Estrella Immunopharma, Inc. Common Stock (Healthcare) — a non-dividend-paying stock. Trading at $0.72. Market cap: $32M. Capital Quality Rank: 49/100 — Stagnant mediocrity.
Stock snapshot
| Price | $0.72 |
| Market cap | $32M |
| Sector | Healthcare |
| Exchange | — |
| Pays dividend | No |
Capital Quality & fundamentals
DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.
| Capital Quality Rank (1-100) | 49 / 100 · Stagnant mediocrity |
| Shareholder buyback yield | 0.00% |
| Altman Z-score zone | Distress |
About ESLA
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
Related non-dividend companies
Other non-dividend stocks investors research alongside ESLA. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is ESLA's current stock price?
ESLA (Estrella Immunopharma, Inc. Common Stock) is currently trading at $0.72.
Does ESLA pay a dividend?
ESLA (Estrella Immunopharma, Inc. Common Stock) does not currently pay a regular dividend.
What is ESLA's Capital Quality Rank?
ESLA has a Capital Quality Rank of 49/100 — Stagnant mediocrity. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.
Track ESLA in DiviDrip
Add ESLA to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search ESLA and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed recently. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.